CASP1 and arthritic joint disease: A small number of reversible specific inhibitors of caspase-1 (including VX-740 and VX-765) have entered clinical trials42,43: preclinical studies demonstrated that these inhibitors ameliorate disease severity in models of arthritis and inflammation, but some were withdrawn from clinical trials because of liver toxicity after long-term administration in animal studies.